Changing dosing, administration of anthrax vaccine reduces side effects

Sep 30, 2008

Reducing the number of doses of an anthrax vaccine and changing its administration to intramuscular injection resulted in comparable measures of effectiveness but with fewer adverse events, according to a study in the October 1 issue of JAMA.

"Simpler and better tolerated regimens for vaccination with anthrax vaccine adsorbed (AVA) are needed," the authors write. The licensed AVA vaccination regimen is administered by injection below the skin (subcutaneously) at 0, 2, and 4 weeks and 6, 12 and 18 months, with annual boosters thereafter. Data supporting this regimen are limited.

The Centers for Disease Control and Prevention, Atlanta, in collaboration with several U.S. clinical study sites and the Anthrax Vaccine Research Program Working Group, conducted a randomized clinical trial, which included 1,005 enrollees, to assess safety and serological outcomes of alternative schedules and routes of administration of AVA. Participants received AVA by the subcutaneous (SQ) or intramuscular (IM) route at 0, 2 and 4 weeks and 6 months (4-SQ or 4-IM; n = 165-170 per group) or at a reduced 3-dose schedule (3-IM; n = 501). A control group (n = 169) received saline injections at the same time intervals.

The researchers found that at month 7, after completion of the priming series (1st four injections), all groups had serum antibody responses that were "noninferior to" (i.e., no less than) the licensed regimen. Most injection site adverse events (AEs), such as warmth, tenderness, itching, abnormal redness of the skin and swelling, occurred at lower proportions in the 4-IM group compared with the 4-SQ group. The odds ratio for ordinal pain (response ranging from no pain to extreme pain) reported immediately after injection was reduced by 50 percent for the 4-IM vs. 4-SQ groups.

"Our data demonstrate that a 3-IM regimen (omission of the week 2 dose) elicits serum antibody responses at month 7 that are noninferior when compared with regimens containing 4 doses of AVA (SQ or IM). Intramuscular administration was associated with a significant reduction in injection site AEs. Changing the injection route from SQ to IM may increase vaccine acceptability. Reducing the number of doses in the AVA regimen would have the added benefit of increasing the number of doses available for prophylactic use," the authors conclude.

Source: JAMA and Archives Journals

Explore further: Researchers take 'first baby step' toward anti-aging drug

add to favorites email to friend print save as pdf

Related Stories

Why the Sony hack isn't big news in Japan

10 hours ago

Japan's biggest newspaper, Yomiuri Shimbun, featured a story about Sony Corp. on its website Friday. It wasn't about hacking. It was about the company's struggling tablet business.

Hopes, fears, doubts surround Cuba's oil future

11 hours ago

One of the most prolific oil and gas basins on the planet sits just off Cuba's northwest coast, and the thaw in relations with the United States is giving rise to hopes that Cuba can now get in on the action.

Ancient clay seals may shed light on biblical era

11 hours ago

Impressions from ancient clay seals found at a small site in Israel east of Gaza are signs of government in an area thought to be entirely rural during the 10th century B.C., says Mississippi State University archaeologist ...

Off-world manufacturing is a go with space printer

14 hours ago

On Friday, the BBC reported on a NASA email exchange with a space station which involved astronauts on the International Space Station using their 3-D printer to make a wrench from instructions sent up in ...

Recommended for you

Biomedical team creates 'nerve on a chip'

Dec 24, 2014

Michael J. Moore and J. Lowry Curley first met in the laboratory as professor and student. Now the two Tulane University researchers have started a new biomedical company that's winning praise and awards.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.